Staphylococcus aureus News and Research

RSS

Staphylococcus aureus is a spherical bacterium (coccus) which on microscopic examination appears in pairs, short chains, or bunched, grape-like clusters. These organisms are Gram-positive. Some strains are capable of producing a highly heat-stable protein toxin that causes illness in humans.

MRSA pathogen influences U.S. physician drug selection for treating skin structure infections

Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that methicillin-resistant Staphylococcus aureus (MRSA) is the most concerning pathogen to surveyed U.S. physicians with regard to their treatment of skin and skin structure infections.

8 Oct 2010

Scientists engineer bacterial cell wall with small molecules to combat diseases

A team of Yale University scientists has engineered the cell wall of the Staphylococcus aureus bacteria, tricking it into incorporating foreign small molecules and embedding them within the cell wall.

8 Oct 2010

UCI awarded $10M grant to explore ways of preventing staph infections in people harboring MRSA bacteria

A UC Irvine infectious disease specialist has received a three-year, $10 million grant to explore the effectiveness of new methods to prevent staph infections in people who harbor MRSA bacteria when they're discharged from the hospital.

4 Oct 2010

NIH awards Polymedix $986,000 to develop defensin mimetic antimicrobial compounds for oral candidiasis

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has received a Phase 2 grant in the amount of $986,000 from the National Institute of Health (NIH) to support the development of defensin mimetic antimicrobial compounds for the treatment of oral candidiasis. This grant will fund this research project through August 31, 2012. This award represents the 14th grant or research contract received to date by PolyMedix.

30 Sep 2010

MRSA survivors to share experience at World MRSA Day kickoff event

No one needs to explain to the people who have experienced it the danger posed by methicillin-resistant Staphylococcus aureus, the antibiotic-defying bacterium commonly known as MRSA. No one needs to explain to the people who have experienced it the danger posed by methicillin-resistant Staphylococcus aureus, the antibiotic-defying bacterium commonly known as MRSA.

29 Sep 2010

NIH grants Akonni $3M for development of multi-drug resistant/extensively drug-resistant genotyping test

Akonni Biosystems, a molecular diagnostics company that develops, manufactures, and plans to market sophisticated genetic testing devices for complex infectious and human diseases, today announced receipt of a nearly $3 million Challenge Grant from the National Institutes of Health (NIH), a new program made possible under the American Recovery and Reinvestment Act (ARRA).

29 Sep 2010

PolyMedix begins PMX-30063 Phase 2 clinical trial for bacterial infections

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 2 clinical trial in Canada with its novel defensin-mimetic antibiotic, PMX-30063.

28 Sep 2010

NC State receives $1.8M defense grant to test molecule efficacy against antibiotic-resistant infections

A new $1.8 million grant from the Department of Defense will allow North Carolina State University researchers to work with the Walter Reed Institute of Research to further test the effectiveness of molecules that have shown great promise in combating antibiotic-resistant infections.

23 Sep 2010

MDI and Integrated Sciences enter exclusive distribution agreement for Detect-Ready MRSA assay in Australia

Molecular Detection Inc. (MDI), a company developing Detect-Ready™ assays designed to increase the speed and accuracy of infectious disease diagnosis, and Integrated Sciences Pty. Ltd. today announced that they have entered into an exclusive distribution agreement for MDI's Detect-Ready MRSA assay in Australia.

22 Sep 2010

New anti-pathogenic drugs render MRSA harmless without killing bacteria

Menachem Shoham, PhD, associate professor and researcher in the department of biochemistry at the Case Western Reserve University School of Medicine, has identified new anti-pathogenic drugs that, without killing the bacteria, render Methicillin Resistant Staphylococcus Aureus (MRSA) harmless by preventing the production of toxins that cause disease.

17 Sep 2010

PolyMedix presents defensin mimetic antibiotics data at ICAAC Conference

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, today presented five posters at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

16 Sep 2010

Tetraphase Pharmaceuticals presents preclinical data of TP-434 antibacterial drug

Tetraphase Pharmaceuticals, Inc., today presented encouraging preclinical data for its lead drug candidate, TP-434, which showed the potent antibacterial activity of TP-434 against a very broad spectrum of susceptible and multidrug-resistant pathogens.

16 Sep 2010

ViroPharma presents Phase 1 study data of VP20621 at ICAAC 2010

ViroPharma Incorporated today announced the presentation of data from its Phase 1 study of VP20621 (non-toxigenic Clostridium difficile), a novel treatment approach for preventing recurrent Clostridium difficile infections, a common and dangerous gastrointestinal infection typically occurring in older adults after use of antibiotic medications.

16 Sep 2010

Scientist to develop antibiotics for drug-resistant superbugs

Antibiotics can work miracles, knocking out common infections like bronchitis and tonsillitis. But according to the Center for Disease Control, each year 90,000 people in the U.S. die of drug resistant "superbugs" bacteria like Staphylococcus aureus (MRSA), a deadly form of staph infection resistant to normal antibiotics. Although hospital patients are particularly susceptible as a result of open wounds and weakened immune systems, the bacteria can infect anyone. Dr. Micha Fridman of Tel Aviv University's Department of Chemistry is now developing the next generation of antibiotics designed to overcome this kind of bacteria. And the key, he says, is in the bacteria itself.

15 Sep 2010

Excelimmune presents positive results for HRPA therapy against MRSA infections

Excelimmune, Inc. announced positive results from preclinical studies evaluating the efficacy of its human recombinant polyclonal antibody (HRPA) therapy against infections caused by methicillin-resistant Staphylococcus aureus (MRSA).

14 Sep 2010

NIH awards QuantaLife $6 million to build platform for detecting MRSA infections

QuantaLife, a new life science tool company developing the third generation of PCR, has received an NIH grant totaling ~$6 million over 5 years for the development of rapid, cost-effective technology for detecting methicillin-resistant Staphylococcus aureus (MRSA) infections. The grant, from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the National Institutes of Health, will fund the project.

14 Sep 2010

Trius Therapeutics reports torezolid antibiotic resistance mechanism for MRSA strains

Trius Therapeutics, Inc. today reported new findings on torezolid phosphate (TR-701), a second generation oxazolidinone antibiotic now in Phase 3 clinical development. The data elucidate the mechanism by which torezolid retains full activity against clinical isolates of Staphylococcus aureus (S. aureus) carrying the cfr gene which confers resistance to first generation oxazolidinones such as linezolid, marketed by Pfizer as Zyvox.

14 Sep 2010

Rib-X Pharmaceuticals presents preclinical data of radezolid drug at ICAAC Conference

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced the presentation of positive preclinical data for radezolid at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) conference.

13 Sep 2010

MRSA infection hVISA linked to mortality

A MRSA infection with a reduced susceptibility to the potent antibiotic drug vancomycin is linked to high mortality, according to a Henry Ford Hospital study.

12 Sep 2010

395 new vaccines being developed for infectious diseases: PhRMA

Critical challenges remain in the centuries-old battles against infectious diseases, particularly as bacteria and viruses mutate and as the threat of bioterrorism grows. Responding to this need, America's biopharmaceutical research companies this year have 395 new medicines and vaccines in the pipeline to fight infectious diseases. All 395 are in later stages of development, meaning in clinical trials or under Food and Drug Administration (FDA) review.

10 Sep 2010

Staphylococcus aureus News and Research

Further Reading

MRSA pathogen influences U.S. physician drug selection for treating skin structure infections

Scientists engineer bacterial cell wall with small molecules to combat diseases

UCI awarded $10M grant to explore ways of preventing staph infections in people harboring MRSA bacteria

NIH awards Polymedix $986,000 to develop defensin mimetic antimicrobial compounds for oral candidiasis

MRSA survivors to share experience at World MRSA Day kickoff event

NIH grants Akonni $3M for development of multi-drug resistant/extensively drug-resistant genotyping test

PolyMedix begins PMX-30063 Phase 2 clinical trial for bacterial infections

NC State receives $1.8M defense grant to test molecule efficacy against antibiotic-resistant infections

MDI and Integrated Sciences enter exclusive distribution agreement for Detect-Ready MRSA assay in Australia

New anti-pathogenic drugs render MRSA harmless without killing bacteria

PolyMedix presents defensin mimetic antibiotics data at ICAAC Conference

Tetraphase Pharmaceuticals presents preclinical data of TP-434 antibacterial drug

ViroPharma presents Phase 1 study data of VP20621 at ICAAC 2010

Scientist to develop antibiotics for drug-resistant superbugs

Excelimmune presents positive results for HRPA therapy against MRSA infections

NIH awards QuantaLife $6 million to build platform for detecting MRSA infections

Trius Therapeutics reports torezolid antibiotic resistance mechanism for MRSA strains

Rib-X Pharmaceuticals presents preclinical data of radezolid drug at ICAAC Conference

MRSA infection hVISA linked to mortality

395 new vaccines being developed for infectious diseases: PhRMA

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News